| Management target | Net Profit FY27 |
|---|
| Margins | EBITDA margin at 30.9%; expected improvement Q-on-Q. |
|---|---|
| Demand visibility | Strong flu season in SA; cyclical orders in international markets. |
| Management confidence | High on oncology pipeline and international diversification. |
Growth
Revenue fell from INR 1,390.6 Cr YoY due to lower Lenalidomide sales. Brazil revenue surged 180% to INR 178 Cr.
Outlook
Management maintained FY27 PAT guidance of INR 750 Cr. Planning INR 2,000 Cr fundraise for potential M&A opportunities.
Risks
Seasonal demand cycles in South Africa; high R&D spend volatility; competitive pricing in the semaglutide market.
Last quarter's promises, checked
Delivered
- Guided FY26 PAT INR 1,400 Cr → delivered INR 1,418.5 Cr (= BEAT)
- Guided FY26 net cash INR 2,400 Cr → delivered INR 2,400 Cr (= BEAT)
- Guided Brazil sub revenue INR 730 Cr → delivered INR 730 Cr (= BEAT)
Partly delivered
- Guided R&D spend 7-9% → delivered elevated Q4 spend due to write-downs (= PARTIAL)
Missed
- Guided FY26 Revenue INR 4,784 Cr → delivered INR 4,375.9 Cr (= MISS)
Investor Presentation filed with BSE, NSE: NATCOPHARM. Summary written with AI assistance from the document.
Natco Pharma Ltd: key numbers
- Share price
- ₹839.30
- Market cap
- ₹15,033 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.1×Sector 50.4×
- Promoter holding
- 49.42%+0.00% QoQ
- FII holding
- 16.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Fund Raise of ₹1,279 Cr
Natco Pharma's board has approved a Rights Issue to raise ₹1,279.36 Crore. The company will issue 17,058,082 equity shares at ₹750 each in a 2:21 ratio.
- Value
- ₹1,279 Cr
Natco Pharma Capital Structure Change
Natco Pharma's board approved a Rights Issue of 1,70,58,082 shares aggregating to ₹1,279.36 Crore. The issue is priced at ₹750 per share with a 2:21 ratio.
- Value
- ₹1,279 Cr
Natco Pharma Board Meeting Date
Natco Pharma will hold a board meeting on 25th September 2026 to finalise terms for its previously approved rights issue, including pricing and record date.
Natco Pharma Capital Structure Change
Natco Pharma has received in-principle approval from BSE and NSE for its upcoming Rights Issue of fully paid-up equity shares.
Natco Pharma Capital Structure Change
Natco Pharma proposes a Rights Issue of equity shares aggregating up to ₹1,300 Crore. The company has filed the Draft Letter of Offer for this capital raise.
- Value
- ₹1,300 Cr
Natco Pharma Fund Raise of ₹1,300 Cr
Natco Pharma board approved a rights issue of up to ₹1,300 crore face value ₹2 equity shares. The demerger scheme will be revised post-completion of the raise.
- Value
- ₹1,300 Cr